Team Startupcity

• Cureous Labs raises  Rs 1.66 Cr seed funding led by IPV and Anthill Ventures.
• Flagship product Eturnal offers affordable automated patient repositioning at one-fifth global prices.
• Over 30,000 usage hours and 14,000 automated patient turns already recorded.

Cureous Labs, a Bengaluru-based medtech startup, has secured  Rs 1.66 crore in seed funding from Inflection Point Ventures (IPV) with follow-on investment from Anthill Ventures.

The capital will be used to produce the initial batch of its star product Eturnal, stockpiling inventory, hiring sales and business development teams, opening its first disinfection centre, and finishing product safety certifications and testing. The firm will also expand its B2B operations in India.

Also Read-Trackk Secures $1 Million to Redefine Stock Trading for Young Investors

Started by Asish Mohandas, Cureous Labs designs computerized patient repositioning systems with the objective to prevent pressure injuries and enhance caregiver productivity. The equipment, costing only a fraction of equivalent overseas options at one-fifth, is made for deployment in hospitals, rehabilitation facilities, and home care.

The firm indicates that its solution has already accumulated over 30,000 operating hours and over 14,000 computerized patient turns.

As per market estimates, the world elderly and bedridden patient care industry is worth $277 billion, with India's total addressable market standing at $8.34 billion.